GEN News Highlights

GE to Spend $200M a Year for Cancer R&D Plus Chips in $50M for Open Innovation Challenge

(Page
1
of
1)

GE Healthcare reported plans to spend $1 billion over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities as well as its technologies for the manufacture of biopharmaceuticals and for cancer research. The firm also announced a $100 million open innovation challenge along with four venture capitalist firms.

The $1 billion is part of the $6 billion GE said it would spend under its healthymagination campaign, which started in May 2009, according to Bloomberg News. The contest will use both direct investments and grant access to the company’s sales force and R&D resources, also awarding $100,000 to universities for research, Bloomberg News adds.

Over the past few years GE Healthcare has been expanding its oncology pipeline and portfolio by spending on acquisitions. Most recently, on August 16, it took over PAA Laboratories, which has offerings for cell biology research and for the discovery and manufacture of biopharmaceuticals. Also this year, in April, GE picked up cellular imaging firm Applied Precision.

In October 2010, the company made an offer to acquire Clarient for about $580 million. The deal forms the backbone of GE’s biomarker and diagnostic focus. Previous company purchases include Amersham (2004), Biacore (2006), Wave Biotech (2007), and MicroCal (2008).

GE Healthcare says that it plans to bolster its current initiatives armed with its $20 million annual cancer R&D budget. Programs span biomarker development, molecular pathology, imaging technologies, biologic production, and IT solutions for healthcare. GE Healthcare expects to introduce new tracers to the FASTlab* multitracer platform, a PET chemistry system on which the company is also developing PET proprietary agents.

The open innovation challenge will run for six months. GE will contribute half the $100 million fund, with the other investors—Kleiner Perkins Caufield & Byers, Venrock Associates, Mohr Davidow Ventures, and MPM Capital LP—chipping in the rest.

The goal is to help healthcare professionals better understand tumors associated with triple negative cancer, a type of cancer that is less responsive to standard treatments and is typically more aggressive; to elucidate molecular similarities between breast cancer and other solid tumors; to improve early detection; and to help doctors make the best possible treatment decisions based on each patient’s unique cancer.

Challenge entrants will be evaluated by a committee of representatives from GE and venture capital partner firms. A separate, independent judging panel will include GE executives, venture capital partners, and several leading healthcare luminaries such as former FDA commissioner and NCI director Andrew Von Eschenbach, M.D.

GE adds that it is investing in the development of a first-in-kind “super database,” which will consolidate clinical, pathology, therapy, and outcomes data in one place to enable analysis and further accelerate innovation.

This super database will be available in collaboration with leading cancer research, NGO, and government organizations. It will start with relevant cancer data from GE’s Medical Quality Improvement Consortium; Clarient, a GE Healthcare company; The Premier healthcare alliance; and the U.S. Department of Health & Human Services.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.